Understanding TYK2 as a Therapeutic Target in the Management of Moderate to Severe Psoriasis

Wednesday, May 3, 2023

10:30 AM – 11:15 AM .

Presenter(s)

Jeffrey Cohen, MD

Assistant Professor of Dermatology and Biomedical Informatics and Data Science; Director, Psoriasis Treatment Program
Yale School of Medicine
Yale School of Medicine
New Haven, Connecticut

Disclosure(s): disclosed no relevant financial relationship with any ineligible company (commercial interest).

Moderator(s)

Joseph F. Merola, MD, MMSc

Vice Chair of Clinical Trials and Innovation
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

Disclosure(s): disclosed no relevant financial relationship with any ineligible company (commercial interest).

JAK inhibitors are associated with toxicities at efficacious doses, including infections, hematologic abnormalities, increases in high- and low-density lipoproteins and triglycerides, and other metabolic effects. TYK2 inhibition has emerged as an alternate strategy for targeting the critical signal linkage between IL-23 and IL-17, thereby providing an improved benefit–risk profile. This session will increase clinicians’ knowledge and understanding of emerging options for the management of PsO in order to optimize clinical outcomes and improve patient QoL.

Learning Objectives:

Describe the role of TYK2 in the pathophysiology and progression of PsO and associated implications for treatment
Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with PsO
Implement strategies to integrate TYK2 inhibitors and shared decision-making into the management of PsO